BACKGROUND: The mechanism behind castration-induced apoptosis in prostate cells is unknown, but data from other species suggest that transforming growth factor beta1 (TGF-beta1) may be involved. METHODS: By using quantitative RT-PCR and immunohistochemistry, expression of TGF-beta1 and its receptors type I and II (RI and RII) was studied in normal and tumor areas of core biopsies taken before and 2-11 days after castration therapy. The TGF-beta responses were related to changes in apoptotic index and to changes in serum prostate-specific antigen (PSA). RESULTS: In normal prostate tissue, apoptosis was generally increased by castration, and apoptosis was accompanied by an increase in TGF-beta1 and RII mRNA levels (P < 0.05). In tumors, apoptosis was seen only in 44% of the cases and in these, but not in the others, TGF-beta1, RI, and RII mRNA levels were increased (P < 0.05). In the patients showing a prognostically favorable PSA response (nadir PSA <5 ng/ml), but not in the others, RI and RII mRNA levels were significantly upregulated (P < 0.05). CONCLUSIONS: Short-term upregulation of TGF-beta1 and its receptors is associated with apoptosis in human prostate and prostate cancer, and possibly with a favorable clinical outcome after castration therapy.
BACKGROUND: The mechanism behind castration-induced apoptosis in prostate cells is unknown, but data from other species suggest that transforming growth factor beta1 (TGF-beta1) may be involved. METHODS: By using quantitative RT-PCR and immunohistochemistry, expression of TGF-beta1 and its receptors type I and II (RI and RII) was studied in normal and tumor areas of core biopsies taken before and 2-11 days after castration therapy. The TGF-beta responses were related to changes in apoptotic index and to changes in serum prostate-specific antigen (PSA). RESULTS: In normal prostate tissue, apoptosis was generally increased by castration, and apoptosis was accompanied by an increase in TGF-beta1 and RII mRNA levels (P < 0.05). In tumors, apoptosis was seen only in 44% of the cases and in these, but not in the others, TGF-beta1, RI, and RII mRNA levels were increased (P < 0.05). In the patients showing a prognostically favorable PSA response (nadir PSA <5 ng/ml), but not in the others, RI and RII mRNA levels were significantly upregulated (P < 0.05). CONCLUSIONS: Short-term upregulation of TGF-beta1 and its receptors is associated with apoptosis in human prostate and prostate cancer, and possibly with a favorable clinical outcome after castration therapy.
Authors: Philip P Fitchev; Susan M Wcislak; Chung Lee; Anders Bergh; Charles B Brendler; Veronica M Stellmach; Susan E Crawford; Constantine D Mavroudis; Mona L Cornwell; Jennifer A Doll Journal: Lab Invest Date: 2010-05-10 Impact factor: 5.662
Authors: Jan C Brase; Marc Johannes; Heiko Mannsperger; Maria Fälth; Jennifer Metzger; Lukasz A Kacprzyk; Tatjana Andrasiuk; Stephan Gade; Michael Meister; Hüseyin Sirma; Guido Sauter; Ronald Simon; Thorsten Schlomm; Tim Beissbarth; Ulrike Korf; Ruprecht Kuner; Holger Sültmann Journal: BMC Cancer Date: 2011-12-05 Impact factor: 4.430
Authors: Sarah N Salm; Patricia E Burger; Sandra Coetzee; Ken Goto; David Moscatelli; E Lynette Wilson Journal: J Cell Biol Date: 2005-06-27 Impact factor: 10.539